ストックスクリーナーアプリを入手
1.59
1.27%
0.02
前日終値:
$1.57
開ける：
$1.6
24時間の取引高:
28,940
Relative Volume:
0.09
時価総額：
$35.11M
収益：
-
当期純損益:
$-16.51M
株価収益率:
-1.1753
EPS:
-1.3528
ネットキャッシュフロー:
$-15.68M
1週間 パフォーマンス:
+3.92%
1か月 パフォーマンス:
-22.44%
6か月 パフォーマンス:
-53.24%
1年 パフォーマンス:
-46.82%
1日の値動き範囲:
$1.57
$1.6188
1週間の範囲:
$1.53
$1.70
52週間の値動き範囲:
$1.45
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
名前
Medicus Pharma Ltd
セクター
電話
610-540-7515
住所
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
MDCX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.57 | 35.11M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,102.81 | 952.34B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.57 | 493.40B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.09 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.81 | 270.22B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
142.44 | 272.99B | 54.45B | 14.42B | 17.15B | 7.333 |
Medicus Pharma Ltd (MDCX) 最新ニュース
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Shelby Star
2026 world cup world class players analysis: Will Medicus Pharma Ltd. Equity Warrant stock benefit from green energy trends2026 world cup usa national team quarterfinals key players low block defense expert forecast expert opinion - Улправда
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025FDL Reporter | The Reporter - fdlreporter.com
Medicus Pharma to present phase 2 data at Biotech Showcase 2026 - Investing.com Nigeria
2026 world cup analysis guide: Why Medicus Pharma Ltd. stock could benefit from AI revolution2026 world cup usa national team group stage top scorers transition play tactical prediction guide - Улправда
Medicus Pharma to highlight multiple Phase 2 catalysts at Biotech Showcase 2026 - Proactive financial news
Medicus Pharma Ramps Up Partnering Push as Phase 2 SkinJect Data Nears - TipRanks
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates - The Manila Times
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as - GlobeNewswire
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights - Victorville Daily Press
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Pekin Daily Times
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome - The Coloradoan
Dated alerts on Medicus Pharma withdrawn - marketscreener.com
What drives Medicus Pharma Ltd stock priceResistance Breakout Alerts & Test Our Stock Screener — Free Forever - earlytimes.in
Medicus Pharma enters equity distribution agreement for up to $15.3 million By Investing.com - Investing.com Australia
Medicus Pharma enters equity distribution agreement for up to $15.3 million - Investing.com Nigeria
Medicus Pharma Launches At-the-Market Equity Offering Program - TipRanks
Medicus Pharma Signs Equity Distribution Agreement With Maxim Group and Yorkville Securities - TradingView — Track All Markets
Medicus Pharma to offer securities worth up to $100 millionSEC filing - marketscreener.com
Medicus Pharma launches at-the-market equity offering program - MSN
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Lubbock Avalanche-Journal
Can Medicus Pharma Ltd stock double in next 5 yearsPortfolio Gains Summary & Low Risk High Win Rate Stock Picks - moha.gov.vn
Medicus Pharma teams with Reliant AI for study push – ICYMI - Proactive financial news
Medicus Pharma’s warrant inducement agreement announced - MSN
Medicus Pharma taps Reliant AI for data-driven Teverelix clinical development - MSN
Medicus Pharma enters non-binding LOI with Reliant AI - MSN
Medicus Pharma appoints new CFO - MSN
Reliant AI Partners with Medicus Pharma to Apply Generative AI in Prostate Cancer Clinical Trials - TipRanks
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Hillsdale Daily News
Medicus Pharma Ltd. To Present at Brookline Capital Markets - Great Falls Tribune
Medicus Pharma (MDCXW) Stock Analysis Report | Financials & Insights - Benzinga
Will Medicus Pharma Ltd. Equity Warrant stock benefit from green energy trendsBullish Engulfing Patterns & Rapid Portfolio Appreciation - bollywoodhelpline.com
Medicus Pharma partners With Reliant AI to advance AI-driven clinical trial analytics - Proactive financial news
Medicus Fills Phase 2 Trial, Eyes FDA Talks for Needle-Free Skin Cancer - MyChesCo
Reliant AI Partners with Medicus Pharma to Apply Generative AI to Clinical Trial Operations - TipRanks
Medicus Pharma Ltd Equity Warrant Stock Analysis and ForecastREITs Market Trends & Affordable Portfolio Strategies - earlytimes.in
Heatmap Data Shows High Activity in Bliss GVS Pharma Limited SectorCapital Gains Strategies & Superior Wealth Growth - Bollywood Helpline
Medicus Pharma Taps Reliant AI for Data-Driven Teverelix Clinical Development - TipRanks
Medicus Pharma signs non-binding AI collaboration to support clinical trials - Proactive financial news
Medicus Pharma Ltd. Announces Engagement with Reliant AI to Develop Artificial- Intelligence (AI) Driven Clinical Data Analytics Platform - marketscreener.com
Medicus Pharma Ltd (MDCX) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
0.93%
大文字化:
|
ボリューム (24 時間):